Multi-target Design Strategies in the Context of Alzheimer’s Disease: Acetylcholinesterase Inhibition and NMDA Receptor Antagonism as the Driving Forces

Neurochemical Research

Volumn 39, Issue 10, 2014, Pages 1914-1923

  Rosini, Michela ^a   Simoni, Elena ^a   Minarini, Anna ^a   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acetylcholinesterase inhibition; Alzheimer s disease; Multi target directed ligands; Multifactorial disease; NMDAR antagonism

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CARBAZOLE DERIVATIVE; CARVEDILOL; CHOLINESTERASE INHIBITOR; DIMEBON; DIZOCILPINE; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TACRINE;

ALZHEIMER DISEASE; CHOLINERGIC ACTIVITY; ENZYME INHIBITION; HUMAN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARASYMPATHETIC INNERVATION; REVIEW; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84918793217     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1250-1     Document Type: Review

References (73)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer’s disease. Lancet 377:1019–1031
2. Alzheimer’s Disease International, World Alzheimer Report. http://www.alz.co.uk/research/world-report-2012.WorldAlzheimerReport2012ExecutiveSummary.pdf
3. Melnikova I (2007) Therapies for Alzheimer’s disease. Nat Rev Drug Discov 6:341–342
4. Citron M (2010) Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 9:387–398
5. Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344
6. Peters JU (2013) Polypharmacology—foe or friend? J Med Chem 56:8955–8971
7. Tumiatti V, Bolognesi ML, Minarini A, Rosini M, Milelli A, Matera R, Melchiorre C (2008) Progress in acetylcholinesterase inhibitors for Alzheimer’s disease: an update. Expert Opin Ther Patents 18:387–401
8. Gauthier S, Molinuevo JL (2013) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement 9:326–331
9. Geerts H, Grossberg GT (2006) Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer’s disease. J Clin Pharmacol 46:8S–16S
10. Patel L, Grossberg GT (2011) Combination therapy for Alzheimer’s disease. Drugs Aging 28:539–546
11. Parsons CG, Danysz W, Dekundy A, Pulte I (2013) Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res 24:358–369
12. Greenamyre JT, Young AB (1989) Excitatory amino acids and Alzheimer’s disease. Neurobiol Aging 10:593–602
13. Wenk GL, Danysz W, Mobley SL (1994) Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Res 655:7–11
14. Allen TG, Abogadie FC, Brown DA (2006) Simultaneous release of glutamate and acetylcholine from single magnocellular “cholinergic” basal forebrain neurons. J Neurosci 26:1588–1595
15. http://www.adamaspharma.com/PR20121505.aspx
16. Morphy R, Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 48:6523–6543
17. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 51:347–372
18. Bolognesi ML, Matera R, Minarini A, Rosini M, Melchiorre C (2009) Alzheimer’s disease: new approaches to drug discovery. Curr Opin Chem Biol 13:303–308
19. Morphy R, Rankovic Z (2007) Fragments, network biology and designing multiple ligands. Drug Discov Today 12:156–160
20. Bolognesi ML, Simoni E, Rosini M, Minarini A, Tumiatti V, Melchiorre C (2011) Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer’s disease. Curr Top Med Chem 11:2797–2806
21. Bolognesi ML (2013) Polypharmacology in a single drug: multitarget drugs. Curr Med Chem 20:1639–1645
22. Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V (2013) Multifunctional tacrine derivatives in Alzheimer’s disease. Curr Top Med Chem 13:1771–1786
23. Leon R, Garcia AG, Marco-Contelles J (2013) Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev 33:139–189
24. Melchiorre C, Andrisano V, Bolognesi ML, Budriesi R, Cavalli A, Cavrini V, Rosini M, Tumiatti V, Recanatini M (1998) Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer’s disease. J Med Chem 41:4186–4189
25. Bartus RT, Dean RL 3rd, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414
26. Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495–529
27. Roberson ED, Mucke L (2006) 100 years and counting: prospects for defeating Alzheimer’s disease. Science 314:781–784
28. Silman I, Sussman JL (2005) Acetylcholinesterase: ‘classical’ and ‘non-classical’ functions and pharmacology. Curr Opin Pharmacol 5:293–302
29. Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Melchiorre C (2008) From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer’s disease. Mini-Rev Med Chem 8:960–967
30. Munoz-Torrero D (2008) Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer’s disease. Curr Med Chem 15:2433–2455
31. Castro A, Martinez A (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 12:4377–4387
32. Viayna E, Sabate R, Munoz-Torrero D (2013) Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. Curr Top Med Chem 13:1820–1842
33. Danysz W, Parsons CG (2012) Alzheimer’s disease, beta-amyloid, glutamate, NMDA receptors and memantine—searching for the connections. Br J Pharmacol 167:324–352
34. Lipton SA (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5:160–170
35. Nyakas C, Granic I, Halmy LG, Banerjee P, Luiten PG (2011) The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-beta42 with memantine. Behav Brain Res 221:594–603
36. Lysko PG, Lysko KA, Webb CL, Feuerstein G, Mason PE, Walter MF, Mason RP (1998) Neuroprotective activities of carvedilol and a hydroxylated derivative: role of membrane biophysical interactions. Biochem Pharmacol 56:1645–1656
37. Howlett DR, George AR, Owen DE, Ward RV, Markwell RE (1999) Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem J 343(Pt 2):419–423
38. Rosini M, Simoni E, Bartolini M, Cavalli A, Ceccarini L, Pascu N, McClymont DW, Tarozzi A, Bolognesi ML, Minarini A, Tumiatti V, Andrisano V, Mellor IR, Melchiorre C (2008) Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer’s disease: a promising direction for the multi-target-directed ligands gold rush. J Med Chem 51:4381–4384
39. Rosini M, Andrisano V, Bartolini M, Bolognesi ML, Hrelia P, Minarini A, Tarozzi A, Melchiorre C (2005) Rational approach to discover multipotent anti-Alzheimer drugs. J Med Chem 48:360–363
40. Rosini M, Simoni E, Bartolini M, Tarozzi A, Matera R, Milelli A, Hrelia P, Andrisano V, Bolognesi ML, Melchiorre C (2011) Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer’s disease. Eur J Med Chem 46:5435–5442
41. Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C (2010) Tacrine derivatives and Alzheimer’s disease. Curr Med Chem 17:1825–1838
42. Pi R, Mao X, Chao X, Cheng Z, Liu M, Duan X, Ye M, Chen X, Mei Z, Liu P, Li W, Han Y (2012) Tacrine-6-ferulic acid, a novel multifunctional dimer, inhibits amyloid-beta-mediated Alzheimer’s disease-associated pathogenesis in vitro and in vivo. PLoS One 7:e31921
43. Huang WY, Chao XJ, Ouyang Y, Liu AM, He XX, Chen MH, Wang LH, Liu J, Yu SW, Rapposelli S, Pi RB (2012) Tacrine-6-ferulic acid, a novel multifunctional dimer against Alzheimer’s disease, prevents oxidative stress-induced neuronal death through activating Nrf2/ARE/HO-1 pathway in HT22 cells. CNS Neurosci Ther 18:950–951
44. Zhang H, Mak S, Cui W, Li W, Han R, Hu S, Ye M, Pi R, Han Y (2011) Tacrine(2)-ferulic acid, a novel multifunctional dimer, attenuates 6-hydroxydopamine-induced apoptosis in PC12 cells by activating Akt pathway. Neurochem Int 59:981–988
45. Parsons CG, Stoffler A, Danysz W (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse. Neuropharmacology 53:699–723
46. Grossberg GT, Edwards KR, Zhao Q (2006) Rationale for combination therapy with galantamine and memantine in Alzheimer’s disease. J Clin Pharmacol 46:17S–26S
47. Busquet P, Capurro V, Cavalli A, Piomelli D, Reggiani A, Bertorelli R (2012) Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice. J Pharmacol Sci 120:305–309
48. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C, Radina M, Zerlin M, Ullmer C, Pereira EF, Lubbert H, Albuquerque EX, Maelicke A (2003) Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 305:1024–1036
49. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Niidome T, Sugimoto H, Fujii T, Okabe S, Akaike A (2006) Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity. Eur J Pharmacol 549:19–26
50. Simoni E, Daniele S, Bottegoni G, Pizzirani D, Trincavelli ML, Goldoni L, Tarozzo G, Reggiani A, Martini C, Piomelli D, Melchiorre C, Rosini M, Cavalli A (2012) Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer’s disease. J Med Chem 55:9708–9721
51. Liu Z, Lv C, Zhao W, Song Y, Pei D, Xu T (2012) NR2B-containing NMDA receptors expression and their relationship to apoptosis in hippocampus of Alzheimer’s disease-like rats. Neurochem Res 37:1420–1427
52. Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009) Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 157:1301–1317
53. Chazot PL (2004) The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem 11:389–396
54. Lopes JP, Tarozzo G, Reggiani A, Piomelli D, Cavalli A (2013) Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav 3:67–74
55. Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A (2006) Acetylcholinesterase inhibitors used in treatment of Alzheimer’s disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51:474–486
56. Burns A, Jacoby R (2008) Dimebon in Alzheimer’s disease: old drug for new indication. Lancet 372:179–180
57. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet 372:207–215
58. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N (2001) Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci 939:425–435
59. Miller G (2010) Pharmacology. The puzzling rise and fall of a dark-horse Alzheimer’s drug. Science 327:1309
60. Portoghese PS (2001) From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J Med Chem 44:2259–2269
61. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S (1996) Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer’s disease. J Biol Chem 271:23646–23649
62. Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E, Cattaneo A, Recanatini M, Melchiorre C (2007) A small molecule targeting the multifactorial nature of Alzheimer’s disease. Angew Chem Int Ed Engl 46:3689–3692
63. Minarini A, Milelli A, Tumiatti V, Rosini M, Simoni E, Bolognesi ML, Andrisano V, Bartolini M, Motori E, Angeloni C, Hrelia S (2012) Cystamine–tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer’s disease treatment. Neuropharmacology 62:997–1003
64. Bolognesi ML, Chiriano G, Bartolini M, Mancini F, Bottegoni G, Maestri V, Czvitkovich S, Windisch M, Cavalli A, Minarini A, Rosini M, Tumiatti V, Andrisano V, Melchiorre C (2011) Synthesis of monomeric derivatives to probe memoquin’s bivalent interactions. J Med Chem 54:8299–8304
65. Bolognesi ML, Bartolini M, Mancini F, Chiriano G, Ceccarini L, Rosini M, Milelli A, Tumiatti V, Andrisano V, Melchiorre C (2010) Bis(7)-tacrine derivatives as multitarget-directed ligands: focus on anticholinesterase and antiamyloid activities. ChemMedChem 5:1215–1220
66. Tumiatti V, Milelli A, Minarini A, Rosini M, Bolognesi ML, Micco M, Andrisano V, Bartolini M, Mancini F, Recanatini M, Cavalli A, Melchiorre C (2008) Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. J Med Chem 51:7308–7312
67. Tumiatti V, Andrisano V, Banzi R, Bartolini M, Minarini A, Rosini M, Melchiorre C (2004) Structure–activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. J Med Chem 47:6490–6498
68. Tumiatti V, Rosini M, Bartolini M, Cavalli A, Marucci G, Andrisano V, Angeli P, Banzi R, Minarini A, Recanatini M, Melchiorre C (2003) Structure–activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. J Med Chem 46:954–966
69. Campiani G, Fattorusso C, Butini S, Gaeta A, Agnusdei M, Gemma S, Persico M, Catalanotti B, Savini L, Nacci V, Novellino E, Holloway HW, Greig NH, Belinskaya T, Fedorko JM, Saxena A (2005) Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors. J Med Chem 48:1919–1929
70. Reinke AA, Gestwicki JE (2011) Insight into amyloid structure using chemical probes. Chem Biol Drug Des 77:399–411
71. Rosini M, Simoni E, Bartolini M, Soriano E, Marco-Contelles J, Andrisano V, Monti B, Windisch M, Hutter-Paier B, McClymont DW, Mellor IR, Bolognesi ML (2013) The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. ChemMedChem 8:1276–1281
72. Bartolini M, Andrisano V (2010) Strategies for the inhibition of protein aggregation in human diseases. ChemBioChem 11:1018–1035
73. Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M (2001) Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons. J Neural Transm 108:459–473